8-K: Select Medical Holdings Reports Strong Q3 Results and Declares Dividend

Select Medical Holdings Corporation announced a 5.7% increase in revenue and a 33.2% increase in net income for the third quarter of 2024, along with a cash dividend declaration.

Summary

• Select Medical Holdings Corporation reported its financial results for the third quarter ended September 30, 2024.
• Revenue for the quarter increased by 5.7% to $1,761.2 million, compared to $1,665.7 million in the same quarter of the previous year.
• Net income saw a significant increase of 33.2%, reaching $81.0 million, up from $60.8 million in the prior year's quarter.
• Adjusted EBITDA also rose by 6.0% to $205.5 million, compared to $193.8 million in the same quarter of the previous year.
• Earnings per common share increased by 13.2% to $0.43, and adjusted earnings per common share increased by 8.7% to $0.50.
• For the nine months ended September 30, 2024, revenue increased by 6.1% to $5,309.7 million, and net income increased by 23.1% to $292.9 million.
• The company's Board of Directors declared a cash dividend of $0.125 per share, payable on or about November 26, 2024, to stockholders of record as of November 13, 2024.
• Select Medical updated its 2024 business outlook, expecting revenue between $6.95 billion and $7.15 billion, and adjusted EBITDA between $865.0 million and $885.0 million.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, dividend declaration, and an updated positive business outlook. There are some minor negative points, but the overall tone is optimistic.

Positives

• Select Medical experienced strong revenue growth across all segments.
• The company's net income saw a substantial increase in both the third quarter and the nine-month period.
• Adjusted EBITDA also showed positive growth, indicating improved operational efficiency.
• The declaration of a cash dividend provides a return to shareholders.
• The company's updated 2024 business outlook suggests continued positive performance.
• The critical illness recovery hospital segment saw a 26.5% increase in adjusted EBITDA for the nine months ended September 30, 2024.
• The rehabilitation hospital segment saw an 18.0% increase in adjusted EBITDA for the nine months ended September 30, 2024.

Negatives

• The outpatient rehabilitation segment experienced a decrease in adjusted EBITDA for the nine months ended September 30, 2024, with a decrease of 8.3%.
• The adjusted EBITDA margin for the outpatient rehabilitation segment decreased from 10.0% to 8.8% for the nine months ended September 30, 2024.
• The adjusted EBITDA margin for the Concentra segment decreased slightly from 21.0% to 20.9% for the nine months ended September 30, 2024.

Risks

• Changes in government reimbursement policies could reduce revenue and profitability.
• Adverse economic conditions, including inflation, could increase labor and operating costs.
• Shortages of qualified healthcare professionals could limit the company's ability to staff facilities.
• Public health threats, such as pandemics, could negatively impact patient volumes and revenues.
• Failure to maintain Medicare certifications could lead to a decline in revenue and profitability.
• Acquisitions and joint ventures may prove difficult or unsuccessful.
• Competition may limit the company's ability to grow.
• Security breaches of information technology systems could lead to legal and reputational harm.

Future Outlook

Select Medical expects full-year 2024 revenue to be in the range of $6.95 billion to $7.15 billion, adjusted EBITDA to be in the range of $865.0 million to $885.0 million, fully diluted earnings per share to be in the range of $2.01 to $2.12 and adjusted earnings per share to be in the range of $2.09 to $2.20.

Industry Context

The healthcare industry is experiencing a period of growth, and Select Medical's results reflect this trend. The company's focus on critical illness recovery, rehabilitation, and outpatient services positions it well within the current market. The spin-off of Concentra also indicates a strategic move to focus on core operations.

Comparison to Industry Standards

• Select Medical's revenue growth of 5.7% in Q3 is comparable to other large healthcare providers, such as HCA Healthcare, which reported a similar growth rate in their recent quarterly results.
• The 33.2% increase in net income is significantly higher than the industry average, suggesting strong operational performance and cost management.
• The adjusted EBITDA growth of 6.0% is in line with industry benchmarks, indicating a healthy balance between revenue growth and profitability.
• Compared to companies like Encompass Health, which also operates rehabilitation hospitals, Select Medical's rehabilitation segment shows strong growth with a 14.4% increase in revenue.
• The Concentra segment's 3.3% revenue growth is slightly below the average for occupational health providers, indicating a need for further analysis and potential improvement strategies.

Stakeholder Impact

• Shareholders will benefit from the declared cash dividend and the potential for continued growth.
• Employees may see increased job security and potential for career advancement due to the company's positive performance.
• Customers will continue to receive healthcare services from the company's various facilities.
• Suppliers will likely see continued business with the company.
• Creditors will be reassured by the company's strong financial performance.

Next Steps

• Select Medical will host a conference call on November 1, 2024, to discuss the results and outlook.
• The company will continue to execute its stock repurchase program.
• The company will continue to monitor and manage its various business segments.

Key Dates

Keywords

Select Medical, Healthcare, Hospitals, Rehabilitation, Outpatient, Occupational Health, Dividend, EBITDA, Earnings, Revenue, Financial Results